Wayne, PA - Recent filings with the SEC reveal notable insider transactions involving Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, Inc. (NASDAQ:PVLA). On May 20, 2026, Ms. Goin sold common stock valued at an approximate total of $475,630. This transaction involved the disposition of 4,302 shares of Palvella's common stock.
Details surrounding the sale indicate that the shares were transacted across a price range spanning from $109.87 to $111.83 per share. It is noteworthy that the current market trading price for PVLA stands at $113.99, representing a considerable appreciation of 424% over the preceding year.
Complementing the sale activity, Ms. Goin also engaged in an acquisition of company stock on the same date. Specifically, she acquired 4,302 shares of common stock through the exercise of existing stock options. These exercised options were valued at prices between $7.14 and $9.08 per share, amounting to a total cost of approximately $34,883.
The documentation confirms that all reported trades conducted by Ms. Goin were executed under the framework of a Rule 10b5-1 trading plan. This plan was initially adopted on August 19, 2025. The establishment of this plan occurred during an open trading window when Ms. Goin confirmed she did not possess any material non-public information, and its implementation followed a review and approval process consistent with Palvella Therapeutics' Insider Trading Policy.
Following the completion of these transactions, reports indicate that Ms. Goin's direct personal holding of Palvella Therapeutics common stock has been reduced to zero shares.
Corporate and Clinical Developments
Beyond the reported insider trading activity, several significant corporate updates define Palvella’s recent operational landscape. From an analytical perspective provided by InvestingPro, the stock is currently valued above its assessed Fair Value, leading to its designation on the Most Overvalued list. Despite facing certain profitability hurdles, analysis from InvestingPro Tips points out a key financial strength: the company maintains more cash than debt on its balance sheet.
In terms of clinical progress, Palvella Therapeutics Inc. has presented promising data derived from two major studies. These include the Phase 3 SELVA study and the Phase 2 TOIVA trial. For the SELVA investigation, results demonstrated significant improvement among participants suffering from microcystic lymphatic malformations; specifically, all 13 young participants were rated as either